Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e158-9. doi: 10.1097/QAI.0b013e31829baf03.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Atazanavir Sulfate
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Hyperbilirubinemia / chemically induced*
  • Hyperbilirubinemia / epidemiology*
  • Infant, Newborn
  • Oligopeptides / adverse effects*
  • Oligopeptides / therapeutic use
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy
  • Pregnant Women
  • Prevalence
  • Pyridines / adverse effects*
  • Pyridines / therapeutic use
  • Risk Assessment

Substances

  • Anti-HIV Agents
  • Oligopeptides
  • Pyridines
  • Atazanavir Sulfate